Subscribe

Tuesday, December 15, 2015 Presented by Ali McBride

Ali McBride, PharmD, MS, BCPS
Clinical Coordinator
The University of Arizona Cancer Center
Tucson, AZ
This peer-delivered program, brought to you by Takeda, will include a clinical overview of NINLARO and its product attributes.

Related Items

An Expert Perspective on the Current and Future of Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Paula Anastasia, RN, MN, AOCN; Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators, Video
Immunotherapy in Combination with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Paula Anastasia, RN, MN, AOCN; Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators, Video
Adverse Events and Improvements in Quality of Life Associated with First-Line Maintenance Therapy in Ovarian Cancer
By Paula Anastasia, RN, MN, AOCN; Ali McBride, PharmD, MS, BCPS
Videos
Interview with the Innovators, Video
Management of Adverse Events Associated with PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
Combination Therapy as Maintenance in Ovarian Cancer
By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
Clinical Data on First-Line Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
Choosing Among PARP Inhibitors as Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
Choosing Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
A Review of Clinical Trials Suggesting the Use of PARP Inhibitors as First-Line Maintenance Therapy in Ovarian Cancer
By Amina Ahmed, MD; Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video
The Impact of Germline or Somatic HRD Testing on Treatment Decisions in Ovarian Cancer
By Ali McBride, PharmD, MS, BCPS; Paula Anastasia, RN, MN, AOCN
Videos
Interview with the Innovators, Video

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

Sign Up for The Oncology Nurse®‑APN/PA

Subscribe to receive the free, monthly TON print publication and TON weekly e‑newsletter.

Subscribe
© Amplity Health. All Rights Reserved. Privacy Policy.